|Articles|November 1, 2003
- Pharmaceutical Technology-11-01-2003
- Volume 2003 Supplement
- Issue 5
21 CFR Part 11: Where Are We Now?
Author(s)William Goebel
FDA's revised guidance on 21 CFR Part 11 offers relief to the regulated industry by providing for enforcement discretion and suggesting a risk-based approach to compliance.
Advertisement
Articles in this issue
over 22 years ago
Improving the Management of Batch Recordsover 22 years ago
Understanding Data, Symbol, and Technology Optionsover 22 years ago
Web Services in Pharmaceutical Manufacturingover 22 years ago
Integrated Compliance ManagementNewsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Drug Digest: Outsourcing Partnerships Fuel Global Biopharma Discovery and Scale-Up
2
Women in STEM: Early Phase Drug Development
3
Rare Disease Treatments: Navigating the Economics of Global Innovation
4
FDA Grants Priority Review For Pfizer’s Marstacimab for Hemophilia A or B
5